Emisphere, Novartis expand pact; Millipore/Merck deal approved by shareholders;

 @FierceBiotech: Burrill: Biopharma no longer a shelter in the storm. Report | Follow @FierceBiotech

 @JohnCFierce: Vertex is currently hiring for more than 130 open positions, including jobs in Cambridge, San Diego & other locations. | Follow @JohnCFierce

 > Emisphere Technologies has entered into an expanded relationship with Novartis. The parties have agreed to modify the royalty and milestone payment schedule for an agreement between the parties for the development of an oral salmon calcitonin product for the treatment of osteoarthritis and osteoporosis. Emisphere release

> Biotech equipment maker Millipore said Thursday its shareholders have approved the company's $6 billion sale to German drug and chemical maker Merck KGaA. Report

> YM BioSciences said Friday it has named Nick Glover to the newly created role of president and chief operating officer. Report

> Scancell Holdings, the developer of therapeutic cancer vaccines, today announces a strategic collaboration with ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings. Under the agreement, Scancell and ImmuneRegen will work together to investigate the synergy between ImmuneRegen's Homspera and Scancell's ImmunoBody vaccine technologies. Release

> Experiments by a team in Glasgow show that blocking a molecule, previously found to be activated during septic shock, cuts the risk of death in mice. Story

> Par Pharmaceutical Companies house announced the resignation of Lawrence Kenyon, executive vice president and chief financial officer, effective June 30, 2010, to pursue other opportunities. Michael Tropiano, Par's treasurer, will replace Kenyon. Release

> Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 (TLR7) and TLR8 in preclinical models of cancer. Release

And Finally... Pfizer and Aspen Pharmacare are being sued over two of their Parkinson's medicines, which some Australian patients say lead to gambling and sex addictions. Report

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.